• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在接受依匹哌唑治疗的精神分裂症患者中，HTR2C-759C/T 多态性与体重增加无关。

Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone.

机构信息

Vanda Pharmaceuticals Inc., Rockville, MD, USA.

出版信息

Psychiatry Res. 2010 Feb 28;175(3):271-3. doi: 10.1016/j.psychres.2009.03.020. Epub 2009 Dec 31.

DOI:10.1016/j.psychres.2009.03.020
PMID:20045196
Abstract

Weight gain is a common side effect of antipsychotics, contributing to poor treatment adherence, and previously linked to the -759C/T polymorphism near the serotonin receptor 2C gene. The effect of this polymorphism was analyzed in schizophrenia patients treated with iloperidone for up to 7 months. No association was detected with the modest weight changes observed in these patients.

摘要

体重增加是抗精神病药物的常见副作用，导致治疗依从性差，先前与位于血清素受体 2C 基因附近的 -759C/T 多态性有关。该多态性的作用在接受伊洛哌酮治疗长达 7 个月的精神分裂症患者中进行了分析。在这些患者中观察到的适度体重变化与该多态性无关。

相似文献

1
Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone.在接受依匹哌唑治疗的精神分裂症患者中，HTR2C-759C/T 多态性与体重增加无关。
Psychiatry Res. 2010 Feb 28;175(3):271-3. doi: 10.1016/j.psychres.2009.03.020. Epub 2009 Dec 31.
2
[Association of antipsychotic agent-induced weight gain with a polymorphism of the promotor region of the 5-HT2C receptor gene].抗精神病药物所致体重增加与5-羟色胺2C受体基因启动子区域多态性的关联
Zhonghua Yi Xue Za Zhi. 2002 Aug 25;82(16):1097-101.
3
[Association of HTR2C-759C/T and -697G/C polymorphisms with antipsychotic agent-induced weight gain].5-羟色胺2C受体基因-759C/T和-697G/C多态性与抗精神病药物所致体重增加的相关性
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008 Apr;33(4):312-5.
4
-759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment.5-羟色胺2C受体基因的-759 C/T多态性与抗精神病药物治疗相关的早期体重增加
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13;31(3):673-7. doi: 10.1016/j.pnpbp.2006.12.021. Epub 2007 Jan 12.
5
HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis.5-羟色胺2C受体单倍型与抗精神病药物所致体重增加：X连锁多标记分析
Hum Psychopharmacol. 2007 Oct;22(7):463-7. doi: 10.1002/hup.868.
6
DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain.多巴胺D4受体基因48碱基对可变数目串联重复序列（DRD4 48 bp VNTR）而非5-羟色胺2C受体基因半胱氨酸23丝氨酸（5-HT 2C Cys23Ser）多态性与抗精神病药物所致体重增加有关。
Pharmacogenomics J. 2009 Feb;9(1):71-7. doi: 10.1038/tpj.2008.5. Epub 2008 Mar 11.
7
[Antipsychotic-induced weight gain--pharmacogenetic studies].[抗精神病药物所致体重增加——药物遗传学研究]
Psychiatr Pol. 2006 Sep-Oct;40(5):1009-20.
8
Genetic predictors of antipsychotic-induced weight gain: a case-matched multi-gene study.抗精神病药物所致体重增加的遗传预测因素：一项病例匹配多基因研究。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Aug;36(8):720-3. doi: 10.3969/j.issn.1672-7347.2011.08.003.
9
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.伊潘立酮治疗精神分裂症急性加重期患者的四周双盲、安慰剂及齐拉西酮对照试验。
J Clin Psychopharmacol. 2008 Apr;28(2 Suppl 1):S20-8. doi: 10.1097/JCP.0b013e318169d4ce.
10
Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.全基因组关联研究中确定的NPAS3基因及其他五个基因座与抗精神病药物伊潘立酮反应的关联
Mol Psychiatry. 2009 Aug;14(8):804-19. doi: 10.1038/mp.2008.56. Epub 2008 Jun 3.

引用本文的文献

1
Association of the HTR2C-759C/T polymorphism and antipsychotic-induced weight gain: a meta-analysis.5-羟色胺2C受体-759C/T多态性与抗精神病药物所致体重增加的相关性：一项荟萃分析。
Gen Psychiatr. 2020 May 14;33(3):e100192. doi: 10.1136/gpsych-2020-100192. eCollection 2020.
2
Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy.伊潘立酮治疗精神分裂症：对其在治疗中地位的循证综述。
Core Evid. 2016 Dec 14;11:49-61. doi: 10.2147/CE.S114094. eCollection 2016.
3
Genetics of Common Antipsychotic-Induced Adverse Effects.
常见抗精神病药物所致不良反应的遗传学
Mol Neuropsychiatry. 2016 Jul;2(2):61-78. doi: 10.1159/000445802. Epub 2016 May 20.
4
Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis.抗精神病药物所致体重增加的药物遗传学关联：一项系统评价和荟萃分析
Schizophr Bull. 2016 Nov;42(6):1418-1437. doi: 10.1093/schbul/sbw058. Epub 2016 May 23.
5
Association between HTR2C gene variants and suicidal behaviour: a protocol for the systematic review and meta-analysis of genetic studies.5-羟色胺受体2C基因变异与自杀行为之间的关联：一项基因研究系统评价与荟萃分析的方案
BMJ Open. 2014 Sep 4;4(9):e005423. doi: 10.1136/bmjopen-2014-005423.
6
Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.在精神分裂症和双相情感障碍的治疗中，阿塞那平、依匹哌酮、鲁拉西酮和帕利哌酮的体重和代谢不良影响：系统评价和探索性荟萃分析。
CNS Drugs. 2012 Sep 1;26(9):733-59. doi: 10.2165/11634500-000000000-00000.
7
Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications.抗精神病药相关体重增加和肥胖相关并发症中瘦素的药物遗传学。
Pharmacogenomics. 2011 Jul;12(7):999-1016. doi: 10.2217/pgs.11.45.
8
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.药物遗传学与抗精神病药：疗效和副作用预测。
Expert Opin Drug Metab Toxicol. 2011 Jan;7(1):9-37. doi: 10.1517/17425255.2011.532787.
9
Assessment of pharmacotherapy for negative symptoms of schizophrenia.评估抗精神分裂症阴性症状的药物治疗。
Curr Psychiatry Rep. 2010 Dec;12(6):563-71. doi: 10.1007/s11920-010-0148-0.